D. E. Shaw & Co., Inc. Alnylam Pharmaceuticals, Inc. Call Options Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

Call Options

20 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$143.31 - $247.0 $11.9 Million - $20.4 Million	-82,700 Reduced 77.8%	23,600 $5.73 Million
Q1 2024 May 15, 2024	BUY	$146.51 - $198.2 $5.76 Million - $7.79 Million	39,300 Added 58.66%	106,300 $15.9 Million
Q4 2023 Feb 14, 2024	BUY	$151.41 - $196.57 $1.57 Million - $2.04 Million	10,400 Added 18.37%	67,000 $12.8 Million
Q3 2023 Nov 14, 2023	BUY	$170.77 - $211.65 $2.25 Million - $2.79 Million	13,200 Added 30.41%	56,600 $10 Million
Q1 2023 May 15, 2023	SELL	$182.66 - $235.53 $1.83 Million - $2.36 Million	-10,000 Reduced 18.73%	43,400 $8.69 Million
Q4 2022 Feb 14, 2023	BUY	$185.53 - $241.31 $2.49 Million - $3.23 Million	13,400 Added 33.5%	53,400 $12.7 Million
Q2 2022 Aug 15, 2022	BUY	$120.42 - $169.29 $1.2 Million - $1.69 Million	10,000 Added 33.33%	40,000 $5.83 Million
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $1.44 Million - $1.88 Million	9,000 Added 42.86%	30,000 $5.09 Million
Q2 2021 Aug 16, 2021	SELL	$128.63 - $176.89 $1.16 Million - $1.59 Million	-9,000 Reduced 30.0%	21,000 $3.56 Million
Q1 2021 May 17, 2021	SELL	$126.83 - $175.69 $2.89 Million - $4.01 Million	-22,800 Reduced 43.18%	30,000 $4.24 Million
Q3 2020 Nov 16, 2020	SELL	$121.19 - $165.49 $2.42 Million - $3.31 Million	-20,000 Reduced 27.47%	52,800 $7.69 Million
Q2 2020 Aug 14, 2020	BUY	$104.21 - $156.44 $1.8 Million - $2.71 Million	17,300 Added 31.17%	72,800 $10.8 Million
Q1 2020 May 15, 2020	BUY	$93.12 - $133.99 $465,600 - $669,950	5,000 Added 9.9%	55,500 $6.04 Million
Q4 2019 Feb 14, 2020	BUY	$74.51 - $124.23 $1.15 Million - $1.93 Million	15,500 Added 44.29%	50,500 $5.82 Million
Q2 2019 Aug 14, 2019	SELL	$65.86 - $92.79 $1.32 Million - $1.86 Million	-20,000 Reduced 36.36%	35,000 $2.54 Million
Q1 2019 May 15, 2019	BUY	$72.76 - $93.45 $291,040 - $373,800	4,000 Added 7.84%	55,000 $5.14 Million
Q4 2018 Feb 14, 2019	BUY	$62.67 - $88.33 $37,602 - $52,998	600 Added 1.19%	51,000 $3.72 Million
Q3 2018 Nov 14, 2018	BUY	$87.52 - $122.67 $3.1 Million - $4.34 Million	35,400 Added 236.0%	50,400 $4.41 Million
Q1 2018 May 15, 2018	BUY	$115.92 - $148.54 $579,600 - $742,700	5,000 Added 50.0%	15,000 $1.79 Million
Q3 2017 Nov 14, 2017	BUY	$72.53 - $118.27 $725,300 - $1.18 Million	10,000	10,000 $1.18 Million

Others Institutions Holding ALNY

# of Institutions

642

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

Capital World Investors Los Angeles, CA

16.5M
Shares

$4.04 Billion
0.73% of portfolio
Vanguard Group Inc Valley Forge, PA

12.6M
Shares

$3.09 Billion
0.06% of portfolio
Black Rock Inc. New York, NY

9.55M
Shares

$2.34 Billion
0.05% of portfolio
Capital Research Global Investors Los Angeles, CA

5.24M
Shares

$1.28 Billion
0.31% of portfolio
Wellington Management Group LLP Boston, MA

4.95M
Shares

$1.21 Billion
0.24% of portfolio

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.1B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account